title: [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
abstract: To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out. We studied the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), and the effects of the combination of HCFU and 2.5-di-O-acetyl-D-glucaro-(1-4)(6-3) dilactone (SLA) which is an anti-beta-glucuronidase agent, for preventive therapy. In the patients treated with HCFU, the recurrence rate was 3.6% and 26.6% one year and two years, respectively, after conservative operation. In the patients treated with both SLA and HCFU, the recurrence rate was lower than in those treated with HCFU one year or more after conservative operation, and a long-term preventive effect was expected for nondrinkers.
authors.affiliation: Department of Urology, Osaka City University Medical School.
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: R
authors.initials: R
authors.lastname: Yasumoto
authors.forename: N
authors.initials: N
authors.lastname: Kashihara
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Maekawa
authors.forename: N
authors.initials: N
authors.lastname: Hayahara
authors.forename: J
authors.initials: J
authors.lastname: Kawakita
authors.forename: T
authors.initials: T
authors.lastname: Nishijima
authors.forename: Y
authors.initials: Y
authors.lastname: Morikawa
authors.forename: A
authors.initials: A
authors.lastname: Horii
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005937:Glucaric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011184:Postoperative Period; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery
chemical_list: C038936:aceglatone; C017367:carmofur; D005937:Glucaric Acid; D005472:Fluorouracil